Our Stocks to Watch tomorrow include Lotta Coal Inc. (OTC: LCOL), Trubion Pharmaceuticals Inc. (Nasdaq: TRBN), Legend Media Inc. (OTCBB: LEGE), Good Life China Corp. (OTC: GLCC), eWorld Companies Inc. (OTC: EWRC) and Helicos BioSciences Corp. (Nasdaq: HLCS).
Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts.
LOTTA COAL (DPOLLUTION) INCORPORATED (OTC: LCOL)
"Up 100.00% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/LCOL.php
Lotta Coal (dpollution) is a publicly traded company that has acquired the manufacturing and distribution rights of a pollution reduction technology. It consists of a series of 3 Patented fuel conditioning devices that improve the combustion efficiency and lower pollution emissions of a gas or diesel engine.
LCOL News:
August 28 - Lotta Coal Launches Its New dpollution Website
Lotta Coal Inc. (OTC: LCOL) (
The launch of the new website comes shortly after the signing of a global exclusive license with Cotren to manufacture and market its patented and revolutionary dpollution technology.
According to independent laboratory tests, the dpollution technology significantly reduces all toxic gases such as 90% reduction in hydrocarbon (HC), 96% in Carbon Monoxide (CO) and also a reduction of 61% in Diatomic Oxygen (O2) making the tested automobile exhaust clean for the environment.
"The dpollution technology is truly revolutionary and it is an affordable solution, which can be implemented immediately to eliminate smog and increase air quality globally," said Bernard Royer, President of Lotta Coal Inc. (dpollution). "Not only can the dpollution product eliminate the deadly gases emitted from automobiles, trucks, and trains, it also increases the efficiency of these engines as well as prolongs their life," further added Mr. Royer.
TRUBION PHARMACEUTICALS INCORPORATED (NASDAQ: TRBN)
"Up 44.91% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/TRBN.php
Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The Company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP, therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the Company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1 clinical evaluation. In addition to Trubion's current clinical stage product pipeline, the Company is also developing its multi-specific SCORPION technology, both for targeting cell-surface molecules like CD79b and HLA-DR, as well as simultaneously neutralizing soluble ligands like TNF and IL-6.
TRBN News:
August 28 - Facet Biotech and Trubion Announce Worldwide Collaboration for the Development and Commercialization of TRU-016
Preliminary clinical data show promise in chronic lymphocytic leukemia; preclinical data support additional indications
Facet Biotech Corporation (Nasdaq: FACT) and Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced an agreement for the joint worldwide development and commercialization of TRU-016, a product candidate in phase 1 clinical development for chronic lymphocytic leukemia (CLL).
TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical (SMIP™) protein therapeutic. The collaboration agreement includes TRU-016 in all indications and all other CD37-directed protein therapeutics.
"TRU-016 is a promising therapeutic with impressive preclinical and preliminary clinical data for CLL that will greatly enhance our pipeline and support a key strategic objective, which is to build a robust oncology portfolio," said Faheem Hasnain, president and CEO of Facet Biotech. "After a thorough evaluation of a number of programs over the past several months, we concluded that TRU-016 was a particularly compelling program and a great fit with our pipeline and expertise. While the novel approach to protein therapeutics is supported by a solid biological rationale and validated clinical data in CLL, TRU-016 may have broad utility in additional indications, including non-Hodgkin's lymphoma and multiple sclerosis. Through this collaboration, we can leverage and extend our significant expertise in the research and development of protein therapeutics and we look forward to playing a key role in advancing this important program with our partners at Trubion."
"In considering alliance opportunities for TRU-016 we sought to retain meaningful economics in this exciting first-in-class product candidate, while enabling aggressive joint development with a partner who shared our vision and brought complementary experience and resources to the alliance," said Peter Thompson, M.D., FACP, president, CEO and chairman of Trubion. "We are delighted to have Facet as our partner. Coupled with our own strengths in the discovery and development of novel protein therapeutics, their expertise will afford us the opportunity to pursue the clinical development and commercialization of TRU-016 and other CD37-directed therapeutics in the most aggressive manner possible."
Under the terms of the collaboration agreement, Trubion will receive an upfront payment of $20 million and may receive up to $176.5 million in additional contingent payments upon the achievement of certain development, regulatory and sales milestones. The companies will share equally the costs of all development, commercialization and promotional activities and all global operating profits. In addition, Facet will purchase 2,243,649 shares of newly issued Trubion common stock for an aggregate purchase price of $10 million.
ABOUT TRU-016
TRU-016 is a novel CD37-directed therapy for the treatment of B-cell malignancies, such as chronic lymphocytic leukemia, or CLL, as well as certain autoimmune and inflammatory disease indications. TRU-016 uses a different mechanism of action than CD20-directed therapies. As a result, its novel design may provide patients with improved therapeutic options and enhance efficacy when used alone or in combination with chemotherapy and/or CD20-directed therapeutics. In June 2009, positive results following preliminary analysis from the Phase 1 clinical trial of TRU-016 for the treatment of CLL were announced. The objectives of the Phase 1 TRU-016 CLL study were to define safety and tolerability, identify a maximum tolerated dose, evaluate pharmacology and pharmacodynamics, and assess preliminary clinical activity.
ABOUT FACET BIOTECH
Facet Biotech is a biotechnology company dedicated to advancing its pipeline of four clinical-stage products, leveraging its research and development capabilities to identify and develop new oncology drugs and applying its proprietary next-generation protein engineering technologies to potentially improve the clinical performance of protein therapeutics. Facet Biotech Corporation launched in December 2008 as a spin-off from PDL BioPharma, Inc.
LEGEND MEDIA INCORPORATED (OTCBB: LEGE)
"Up 81.82% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/LEGE.php
Legend Media (OTCBB: LEGE) is a leading advertising firm in focused on
LEGE News:
August 12 - Legend Media Signs Full-Year Contract With Beijing SouFun Holdings Limited
Legend Media (OTCBB: LEGE) ("Legend Media" or "the Company"), a Chinese multi-media advertising company, announced that the Company has signed a full year contract of RMB1,176,000 (approximately US $172,182 based on the exchange rate as of the date of this press release) to be delivered from July 1, 2009 to June 30, 2010 with Beijing SouFun Holdings Limited for its website www.soufun.com.
Founded in 1999, SouFun.com is
GOOD LIFE CHINA CORPORATION (OTC: GLCC)
"Up 36.36% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/GLCC.php
Good Life China Corporation operates a chain of franchised convenience stores in
GLCC News:
August 28 - Good Life
Good Life China Corporation (OTC: GLCC) announced that its Shenzhen Bread Co. (Miluga) renewed the contract with Ren Ren Le Department Store for moon cake sales in 2009. Ren Ren Le Department Store is one of the biggest chain stores with 22 branches around Shenzhen. It is a popular super center and attracts a large number of consumers.
The sales volume of moon cake can be expected to reach more than USD2 million.
In other company updates: the company would like to use this opportunity to again welcome its shareholders to the company Expo being hosted by its corporate advisors Mina Mar Group and held Aug. 28 in Toronto, Canada at the Marriott Airport location from 12-5 p.m. The company will release images and video of the event on its corporate web site within the next several days.
The Company anticipates making additional announcements regarding major sales contracts in the coming weeks.
EWORLD COMPANIES INCORPORATED (OTC: EWRC)
"Up 44.44% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/EWRC.php
eWorld Companies, Inc. is an online marketing & advertising technologies company that develops and markets cutting edge technologies using rich media, flash, animation and 3D graphics to help individuals and businesses market and advertise online. eWorld's revenue model consists of seven components: (1) Affiliation Fees, (2) Affiliate Monthly Subscriptions, (3) Affiliate Benefit Subscriptions, (4) Product Sales, (5) Advertising Revenues, (6) Web Development Accounts, and (7) International Licensing Fees.
EWRC News:
August 19 - eWorld Companies, Inc. on Track for First Million Boomerang Downloads and Million Dollar Monthly Revenues
Henning Morales, CEO of eWorld Companies, Inc. (OTC: EWRC) announced that the company now expects to generate the first million downloads of its patent-pending Boomerang Media Station and to reach its initial projected goal of $1,000,000 per month in gross profits by the first or second quarter of 2010. This uptick in projections results from three recent events, each of which the eWorld Management Team believes could easily add an additional 500,000 to 1,000,000 Boomerang downloads: the release of Boomerang 4.0 and the launch of the eWorldMix Social Network; the tremendous response to the availability of the Private Label Boomerang; and the current flurry of activity connected with the upcoming eWorld Music Awards.
In recent months the company has also assembled an all-star marketing, branding and event planning team including such noteworthy professionals as Benjamin Torres and Brandi Veil of The Event Division (Emmys, Golden Globes), Diana Zahn-Storey (Independent Spirit Awards, LA Film Festival), Gloria Morrison (Unistar International Pictures) The Compello Exchange and others. Mr. Morales commented, "The responses to our recent activities and upcoming events has been tremendous. We realize that a lot of work remains to be done and there are no guarantees. However, we believe that these projections are conservative and very reachable, and we have never been more excited about our company's near and long term prospects than we are today."
HELICOS BIOSCIENCES CORPORATION (NASDAQ: HLCS)
"Up 36.72% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/HLCS.php
Helicos BioSciences is a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets. Helicos' proprietary True Single Molecule Sequencing (tSMS)(TM) technology allows direct measurement of billions of strands of DNA, enabling scientists to perform experiments and ask questions never before possible. Helicos is a recipient of the $1,000 genome grant and is committed to providing scientists the tools to unlock the era of genomic medicine. The company's corporate headquarters are located at
HLCS News:
August 20 - Ontario Institute for Cancer Research Takes Delivery of a Helicos Genetic Analysis System
Leaders in the field of cancer genomics to leverage benefits of single molecule sequencing technology
Helicos BioSciences Corporation (Nasdaq: HLCS), a life science company focused on innovative genetic analysis technologies, announced the placement of a Helicos™ Genetic Analysis System at the Ontario Institute for Cancer Research (OICR) with Drs. Tom Hudson and John McPherson.
“We are very excited to be working with such a distinguished institution on the application of our technology to the study of cancer genomics” stated Ron Lowy, Helicos Chief Executive Officer.
The Helicos Genetic Analysis System is the world’s first and only commercially available, single molecule sequencing technology, and enables scientists to conduct revolutionary studies in the fields of genome biology, cancer research, common diseases, and microbiology without DNA ligation or amplification. Genetic analysis with Helicos’s technology eliminates the biases, complexity and errors introduced by DNA amplification, requires minute amounts of starting material, and provides the most direct and accurate view of biological samples.
“The translational cancer research we are conducting at our center can benefit greatly from the advantages of single molecule sequencing” stated Tom Hudson, President and Scientific Director of the OICR. “We hope to use this technology for the unbiased and comprehensive characterization of tumor samples to ultimately lead to discoveries that have a clinical impact.”
ABOUT THE ONTARIO INSTITUTE FOR CANCER RESEARCH
The Ontario Institute for Cancer Research is a new research institute, moving
OTCPicks.com is located at
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing.
Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward-looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.
Disclosure: OTCPicks.com has not been compensated by any of the companies covered in this release.
